# FDA Approves Generic Drug Application for Actavis Labs FL Inc Actavis Labs FL Inc received FDA approval for ANDA207139 on June 20, 2017, positioning the company to capture market share in the generic pharmaceutical segment as patent protections expire on the reference drug. The approval expands Actavis's generic portfolio and enhances its competitive positioning in a market increasingly driven by cost-conscious healthcare providers and insurers seeking lower-cost therapeutic alternatives.